PROSTHODONTICS

Tenacious lump of calculus
Sir, as the maxillofacial on-call doctor at Gloucester Royal Hospital, I was asked to assist with the removal of both the upper and lower dentures for a lady who was due for an endoscopy. She had a late presentation for suspected gastric cancer.
The patient had not removed her upper and lower chrome dentures for 15 years! She had irregularly cleaned her teeth with her denture in situ with a toothbrush. During this time she had not needed to attend a dentist, as had no episodes of dental pain, and she explained the dentures had 'attached to her over time'! I eased the upper denture out and was shocked to see the tenacious lump of calculus lingering on the flange as shown in Figs 1-2 -this is after a good scrub with a toothbrush.
The lower was attached to the soft tissue in the floor of the mouth and would have required surgical excision under local anaesthesia, which the patient declined. 
PHARMACOLOGY
Dual therapy guidance
Sir, dental practitioners face an increasing number of medically compromised patients who are on prolonged use of new types of medications for coronary diseases combined with antiplatelet drugs. The invention of new (direct or target) oral anticoagulants (NOACs), including dabigatran, apixaban, and rivaroxaban, which have more favourable pharmacokinetics, as well as a higher safety level, has renewed interest in combination polytherapy.
There is no doubt that dual anticoagulant therapy may have a significant impact on perioperative and postoperative dental care, particularly involving a more complex dental procedure such as oral or periodontal surgery. According to available data, the addition of NOACs to antiplatelet therapy results in a substantial increase in bleeding, most pronounced when NOACs are combined with dual antiplatelet therapy (eg aspirin/ clipodogrel and dabigatran/rivaroxaban). 1 Clinical trials elucidated a dose-dependent increase in major bleeding events, including internal (eg intracranial), with apixaban and rivaroxaban when combined with dual antiplatelet therapy. 2 Since August 2015 recommendations by the Scottish Dental Clinical Effectiveness Programme (SDCEP) in relation to combined antiplatelet and NOACs dual therapy do not advise a specific course of action and they only indicate a need for consultation with a general medical practitioner or specialist. 3 Consultation with an anticoagulation clinic or clinical haematologist is always necessary prior to dental surgery for patients in combined dual anticoagulant therapy due to considerably higher risk of bleeding. Due to the more stable and predictable effects, temporary discontinuation and restarting the NOACs causes less risk than warfarin. When restarting the NOACs, a desirable anticoagulant effect reaches its targeted level within a few hours following administration. 4 International dental guidelines for the new oral anticoagulants are based on a comparison of their bleeding risks with warfarin or low-molecular-weight heparins. Unfortunately, there are no evidence-based guidelines for the dental management of patients receiving these agents. Manufacturers' specifications for NOACs suggest an interruption to anticoagulation therapy prior to only general surgery, 5 but unlike those for warfarin, do not provide separate recommendations for dental and general surgery. For dabigatran a reversal agent was approved in 2015 for use in the setting of urgent procedures or life-threatening bleeding. 6 Hypothetically, it can also potentially be used in emergency cases of severe excessive bleeding following major oral surgery. For rivaroxaban, apixaban, and edoxaban there are no specific antagonist agents reversing the effect of this class of new anticoagulants.
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